This trial is looking at what happens to muscle invasive bladder cancer when adding cevumeran to Nivolumab

Participants will be required to keep all study appointments, tell the study doctor about all medications they are taking, report any side effects to the study doctor.

$202 for each visit completed

This is dietary intervention trial that will examine the impact of consuming three different types of resistant starch on the gut microbiome and butyrate levels in normal weight and obese individuals. Participants will consume starch samples daily for 24 weeks, collecting weekly fecal samples that will be returned to the lab. Researchers will analyze the bacterial fermentation products in these samples, particularly butyrate and analyze the microbiome composition. This will allow identification of differences in resistant starch (a dietary fiber) processing between normal weight and obese individuals and will also determine if the three resistant starches tested have differing impacts on the microbiome and butyrate levels.

The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. The addition of MEDI4736 (durvalumab) immunotherapy to the usual treatment may help shrink your cancer better than the current standard of care or usual approach for bladder cancer. But, it could also cause side effects, which are described in the risks section.This study will help determine if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients by 6 months or more compared to the usual approach.

If you decide to take part in this study, you will either get chemotherapy and radiation for 6-8 weeks, or you will get durvalumab immunotherapy in addition to chemotherapy and radiation for 6.5-8 weeks. After you finish your study treatment, your doctor will continue to follow you for up to 3 years. The follow-up will consist of visits to his or her office and CT scans of the bladder.

This is a Phase 2, multicenter, double-blind, randomized, 52-week study to assess the efficacy and safety of K-001 medication compared with placebo in subjects with noncirrhotic NASH with liver fibrosis. This study will look at a study drug, called K-001, for participants with a liver condition called noncirrhotic nonalcoholic steatohepatitis (NASH). This condition is defined by a build-up of fat in the liver, which causes liver damage and inflammation. Due to this damage, the liver does not work as well. If left untreated, NASH can lead to liver fibrosis (scarring of the liver), liver cancer, or liver failure. K-001 is a once daily pill that contains combination of two medicines: K-877-ER and CSG452. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with NASH with liver fibrosis. To answer these questions, the study drug will be compared with a placebo.

There will be 10 in person visits over 52-week study period. Various procedures will be completed such as a fibroscan, ECG, liver MRI, liver biopsy, blood draws. You will be randomly assigned by chance (like the flip of a coin) to receive the study drugs or placebo (inactive substance). You will be taking a pill once daily.

$1310

There is a growing body of data demonstrating that polyphenols from foods including cocoa and chocolate are metabolized by the gut microbiome to produce small molecular weight metabolites that have greater systemic bioavailability and a potential role in the health-related effects of the parent compounds. The objective of this protocol is to collect fecal samples from human subjects, aged 18 - 40 years old, with overweight or obesity (BMI = 25 – 40 kg/m2), to use as a source of gut microbiota. These fecal samples will be used in in vitro fermentation experiments where fecal samples will be mixed cocoa powder or cocoa extracts in buffer. Samples from these fermentation experiments will be analyzed by chemical methods to identify the metabolites present and will be tested in bioassays to determine potential health-related bioactivities. Because biological sex can impact the composition of the microbiome, we plan to recruit both biological males and females.

There will be two in-person visits. Screening and consent collection will be done at the first and participants will receive supplies for stool collection. The participant will collect the stool samples at home and then return the sample at the second visit.

25

Through in-depth interviews, we examine how the Covid-19 pandemic has impacted the daily lives and mental well-being of essential workers, as well as their use of social media.

This is Phase III study to test whether survodutide (BI 456906) helps people with a liver disease called NASH/MASH who have cirrhosis. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with MASH and liver cirrhosis over a long-term treatment. To answer these questions, the study drug will be compared with a placebo. The overall study duration is approximately 4.5 years.

If you enroll in this study, you will undergo a series of testing. You will be asked to complete an initial assessment that includes a physical exam, vital signs, waist circumference, height, and weight measurements, questionnaires, blood draws, ECG, fibroscan, eye examination, and pregnancy test, if applicable, liver biopsy (if applicable). You will be randomized to either Survodutide once weekly or placebo (an inactive substance of no medical value). For treatment, you will be trained to inject yourself once a week with the study medicine. There will be up to 28 in person visits over 4.5 years study duration - to re-supply the study drug and copmlete safety testing. There will be up to 16 phone calls with the study staff.

up to $3,800 over 4,5 years

The purpose of this study is to determine how effective and safe axi-cel is compared to standard of care, specifically chemo-immunotherapies, and use this information to determine the best choice of treatment in Subjects with Relapsed/Refractory Follicular Lymphoma

Attend all study visits receive study drug or SOChave blood drawn for various testsECHO or MUGA, ECG, PET/CT, and MRI if neededbone marrow biopsy if neededComplete questionnaires

The study will explore the feasibility of using mobile eye-tracking hardware to study how older adults read an informed consent document. The primary objectives are to: (1) characterize gaze (eye-movements) of participants reading a standardized informed consent document using non-invasive mobile eye-tracking hardware, (2) conduct interviews with participants discuss how they read and understood the informed consent document, and (3) evaluate the associations between the data sources to describe how older adults read and understood the informed consent document. Participants will read an informed consent document on a computer on which an eye-tracker is mounted. After reading the document participants will answer surveys related to demographic information, health literacy, and experience with the hardware. They will then complete an interview in which they are asked about their experience reading the informed consent document.

There will be 1 in person visit. During the visit you will be asked to read an informed consent document on a computer screen. You will then answer questions about the consent document, complete an interview about the informed consent document, and complete surveys about your demographic information, health literacy, and experience participating in the study.

$60

Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of resuscitation for sepsis-induced hypotension will reduce 90-day in-hospital mortality.

The new program will help women who have recently been involved in the criminal justice system and use opioids (heroin, fentanyl, prescription pain medications nonmedically) to join treatment programs for opioid addiction. The program will also assist women in finding and getting access to the social services they may need and provide opioid response training. Half of the recruited participants will be randomly selected to be in a trauma support group for women with addiction issues. The program will also help women with common barriers to staying in treatment, such as childcare and transportation.

Participants will be connected to drug treatment programs that offer medications to stop or reduce drug use. Participants will be assigned a peer recovery specialist; these are women in long-term recovery who will help the enrolled women with transportation, childcare, and completing any tasks they may have due to criminal justice involvement or child welfare. Half of our participants will be assigned to a support group of other women in recovery. Participants will complete surveys at three time points and will be paid $50 each time. Participants will also be given overdose response training and take-home-naloxone.

$575

We will conduct a pilot study to test feasibility of an innovative light device and blue-light glasses for promoting better sleep and a novel, smart water bottle for proper hydration. We will also examine women’s sleep and hydration behaviors in relation to their perceptions of pain, and obtain feedback from the participants on the overall patient intervention content to reduce prescription opioid use and promote behavioral pain management strategies after delivery.

Currently recruiting pregnant women who are in their 2nd or 3rd trimester.Attend a pre-session (in person OR remote) to explain the use of the water bottle, lighting devices, activity monitors, and weight scaleUse the devices for 22 days and complete surveys in your own homeAttend a post-session (in person OR remote) to return devices and participate an interview about the last 22 days

$100

The objective of this research is to determine the relationship between aircraft seat width and passenger comfort. Airlines are reducing the sizes of seats and improving their ability to fly planes at or near capacity. The combined effect is to decrease the quality of the experience of passengers. This work will help us to understand the degree to which comfort has been reduced.

Participants visit once, for about an hour. During that visit we will measure several body dimensions. Then the participant will evaluate a number of seating conditions for comfort and acceptability.

$20

Prior to enrollment, potential subjects will be evaluated during the Screening Period to determine eligibility. The following assessments will be performed during the Screening Period:●Review of eligibility ●Placement of hydrogel spacer and fiducial marker after eligibility is determined Visit 2 or Day 2 or Post-test - Radiotherapy per standard of care.

Prior to enrollment, potential subjects will be evaluated during the Screening Period to determine eligibility. The following assessments will be performed during the Screening Period:●Review of eligibility ●Placement of hydrogel spacer and fiducial marker after eligibility is determinedVisit 2 or Day 2 or Post-test - radiotherapy per standard of care

Emerging technologies, particularly in the semiconductor industry, are advancing at an extraordinary pace in the United States, creating an urgent demand for a highly skilled workforce. In 1990, the U.S. held 37% of the global semiconductor manufacturing market; today, that share has sharply declined to just 12% (MASH, 2024). Meanwhile, most semiconductor production has moved overseas, with Taiwan alone accounting for nearly 60% of global output. This concentration of manufacturing capacity in East Asia is increasingly concerning, especially given China’s strategic goal to secure Taiwan by 2030. As such, the U.S. semiconductor supply chain has become a critical national security issue, further emphasizing the immediate need to rebuild a robust domestic manufacturing workforce. To reverse this trend, it is estimated that the U.S. will need an additional 230,000 skilled workers to double its semiconductor market share and regain competitiveness on the global stage (Lightcast, 2023). Achieving this goal requires a significant investment in education and training programs. The HI-TECH (High-Impact Technology Experiential Career Hub) program directly addresses this challenge by offering 75 recent graduates from Career and Technical Education (CTE) programs summer internships in the semiconductor industry over the next three years. These internships will provide invaluable hands-on experience, positioning participants for lucrative, high-demand careers in this vital and rapidly expanding sector. Through this initiative, HI-TECH aims to play a key role in strengthening the U.S. workforce, enhancing national security, and securing America’s future competitiveness in the global semiconductor market.

Participants will be asked to complete an online survey (15-20 minutes) about their experiences with CTE programs, employment in the semiconductor industry, and workforce readiness. Some participants may also be invited to participate in a 30-45 minute interview (conducted via Zoom) to provide further insights.

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements & surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.

this trial is looking at introducing a medication to control blood sugars elevations caused by CDK inhibitors.

Participants must agree to come to all study visits, report any new medications to the study team, agree to having blood work done at least 8-12 hours after eating something, take study medication as directed.

The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment drug (durvalumab), to the usual therapy of radiation plus the drug (cetuximab) in patients with head and neck cancer who cannot take the drug cisplatin.

The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment drug (durvalumab), to the usual therapy of radiation plus the drug (cetuximab) in patients with head and neck cancer who cannot take the drug cisplatin.

Up to 50 older adults (age 60+ years) will participate in a two-visit CRC study with blood sampling (40 ml per visit) occurring before and after a breakfast meal. Specifically, there will be four (10 ml) blood draws during each of the visits, with each blood draw timed one hour apart (T1 to T4). The two visits (short- and long-fasting) will be randomly assigned and counterbalanced for the order in which they occur and will occur at least a week apart. During the short-fasting visit, participants will arrive fasting and be given breakfast after the second blood draw (T2). During the long-fasting visit, participants will arrive fasting and be given breakfast after the fourth blood draw (T4). Aside from blood draws, and vitals obtained at the start of each visit, participants will be seated comfortably in a chair in a small room by themselves. They will be checked upon periodically to ensure they are not falling asleep, they are comfortable, etc. They will also be given a small packet of written questionnaires to complete after T1 and after T3 (i.e., after the 1st and 3rd blood draws). Each visit will be between 3.5 and 4 hours.

There will be two in-person visits both will include four blood draws.

$100 total

This is a survey study that will examine factors that impact the quality of life for parental caregivers of an adult child with profound autism.

Participants will be asked to take a survey about their experiences caring for their autistic adult-child and questions about their well-being.

This trial is using long course chemoradiation in combination with three different chemotherapy treatments to treat rectal cancer. Once therapy is completed patients will either have surgery or watch and wait. The goal is to see which therapy is better in achieving a complete response, if any.

Patients will be expected to come to the clinic for all radiation treatments and all chemotherapy treatments.

This study will provide a strong basis and foundation for future clinical trials that use historical controls. The study will collect clinical data and biological specimens to create a dataset and biorepository to be shared with other researchers as a foundation for future clinical trials.

This is a volunteer study for participants diagnosed with Primary Lateral Sclerosis (PLS) or suspected to have PLS by a neurologist. You will be expected to attend scheduled visits in person or by telephone, complete study testing and audio/video recordings. The study includes clinical measurements to assess disease status and motor function, a number of questionnaires, collection of biospecimens including DNA, blood, and urine, and an electromyography (EMG) test. There will be 6 visits over 24 months, of these 6 three will be in-person visits (2-3 hours) and the other three will be telephone calls (lasting about 45 minutes to an hour). Blood and urine samples will be collected during these visits.

$100 per in person visit (three) and $50 for telephone visit (three) completed.

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

The overall goal of this proposal is to develop robots that can help people correctly calibrate their trust in the robot. We look at this problem within the context of robot-guided emergency evacuation. We believe that robots stationed inside of buildings can serve as instantaneous first responders helping people safely evacuate during an emergency, thus saving lives. Participants will be asked to interact with an emergency guidance robot and decide whether to follow the robot to an exit.

The purpose of this study is to find genetic causes of recurrent pregnancy loss (RPL). RPL is defined by two or more miscarriages under 20 weeks gestation and affects approximately 5% of women.The causes of RPL are not well understood. After all the currently recommended testing for RPL has been done, about half of women with RPL will still have no identifiable cause. This lack of knowledge makes it difficult to provide effective medical care for couples with RPL.This study will compare reading about 20000 genes in the entire human genetic library by whole genome sequencing in the miscarriage material and also your and your partner’s DNA from blood samples. The DNA in a person is a combination of the DNA from each of their biological parents. If you have healthy children we may ask your consent for them to give a blood sample for DNA extraction and testing. Similarly, we may ask the same for other family members such as grandparents if necessary. We may also request your permission to use stored DNA or miscarriage material from previous pregnancy loss if available. Testing of family members or previous miscarriage materials may help to understand DNA sequence variants or changes identified in the miscarriage sample.

There will be a one time collection of blood samples.

This study will follow symptomatic ALS participants and control participants for 2 years, measuring a wide range of ALS outcome measures and gathering long term survival data.

Study visits will be conducted both in an in-clinic setting (on-site) and remotely (off-site) over the course of 24 months (2 years). The symptomatic ALS cohort participants can either participate in on-site or off-site visits, depending on their location and ease of access to one of the participating sites.During this 2-year period, symptomatic ALS participants will complete a screening visit (2-3 hours to complete), a total of 7 in-person study visits (1-3 hours to complete) and 24 remote self-assessment activities (completed each month, takes 35-45 minutes to complete). Participants and will need access to a personal device (i.e. a computer and/or smartphone or tablet) and an internet connection to participate in this study. All control participants will participate on-site, completing their on-site visits every 12 months.Biospecimens will be collected at regular intervals to support biofluid biomarker analyses. Biospecimens will include plasma, serum, whole blood for generation of induced pluripotent stem cells (iPSCs) and DNA for whole genome sequencing, and cerebrospinal fluid (CSF). For on-site symptomatic ALS and control participants, CSF will be collected through optional Lumbar Puncture (LP) procedure. Only plasma, serum and whole blood will be collected for off-site participants through home phlebotomy collection process.

Up to $350

Endometriosis, is a disorder that occurs in women, is when tissue that should be normally found inside the womb is also found in sites outside of the womb. This disorder impairs the function of the endothelium, the cells that line the body’s blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder not only have an increased risk for high blood pressure and high cholesterol, they also have an increased risk for cardiovascular disease. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease. We will test two different intervention strategies to reduce long-term cardiovascular disease risk in women with endometriosis.

There will be 3 in person visits, blood draws will occur at all visits. On 2 of the visits blood flow experiments will be conducted. Participants will take oral medications.

390

This study compares three different functional analysis methods using the same measurements to find the better method. Each participant will be assigned one method to produce a diagram using the given method and one online survey after the in-person experiment. Each participant will be given detailed instructions and information regarding the method to ensure there are no knowledge gaps. 

For the experiment, participants will be assigned to a group of four people from different engineering subfields to evaluate a product using one of three functional analysis methods. Each group will be randomly assigned a product to evaluate and a functional analysis method to use. After the experiment, each participant will be asked to complete an online survey asking for their experiences and thoughts. 

This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for workers.

There will be one in person visit;Subjects will first be asked to sit still for 3 minutes and then move their skin by the research team for another 3 minutes.

This is a study on internet-based self-help for stress related to the COVID-19 pandemic. College and university students who screen high on perceived stress or measures of risk for anxiety, depression, or eating disorders during the COVID-19 pandemic will be invited to participate in this study. Participants will be randomly assigned to receive access to an internet-based self-help program for stress resilience and coping with the COVID-19 pandemic or care as usual. Symptoms of stress, anxiety, depression, and eating disorders, as well as secondary outcomes, will be assessed via questionnaire at baseline (pre-randomization), one month post-randomization, and three months post-randomization.

Participants will be randomly assigned to receive access to an internet-based self-help program for stress resilience and coping with the COVID-19 pandemic or care as usual. Symptoms of stress, anxiety, depression, and eating disorders, as well as secondary outcomes, will be assessed via questionnaire at baseline (pre-randomization), one month post-randomization, and three months post-randomization.

Up to $50 (raffle-based)